Triple Hair

What Triple Hair does

Triple Hair is a clinical-stage Canadian biotechnology company developing prescription and over-the-counter treatments for androgenic alopecia and related hair loss conditions. Founded in 2013 in Dieppe, New Brunswick, by ophthalmologist Dr. Houfar Sekhavat and pharmacist Peter Ford, the company is led by President and CEO Jean-Philippe Gravel. Its flagship product TH07 (Therapy-07) is a patented triple-combination topical spray that combines three FDA-approved active ingredients — minoxidil (5%), finasteride (0.1%), and latanoprost (0.03%) — in a single formulation, simultaneously targeting follicle stimulation, androgen-mediated miniaturization, and growth-cycle prolongation. TH07 is currently in Phase III clinical trials with approximately 920 male patients being enrolled across sites in Canada (420 patients, first dosed April 2026) and India (500 patients, launched May 2026); earlier clinical work reported 82% of participants experiencing moderate to dense hair regrowth versus limited outcomes for monotherapies.

Beyond the prescription pipeline, Triple Hair commercializes a drug-free, natural hair growth line based on its patented TH16 (Therapy-16) formulation under the RIZN brand (for men) and the Plenty Natural brand (for women), sold through owned e-commerce sites (rizn.ca and plentynatural.ca) and white-label partnerships. The company also operates Hair Loss Rx Consult, a Canadian telemedicine platform offering prescription combination treatments via online specialist consultation, and has a distribution agreement with US compounding pharmacy Pharmacy Solutions.

Triple Hair pursues a hybrid go-to-market model: direct-to-consumer e-commerce and telemedicine in Canada, supplemented by international B2B licensing that allows major-market entry without proprietary commercialization infrastructure. Exclusive licensing deals are in place with Aché Laboratórios Farmacêuticos S.A. for Brazil (announced June 2025) and with Akums Drugs & Pharmaceuticals Ltd. for India (announced October 2024); licensees fund regulatory and clinical development, and Triple Hair receives upfront payments, milestone payments, royalties, and (under the Akums arrangement) a 50:50 profit split on distribution sales. To date the company has raised approximately CAD $4M+ across multiple financing rounds, including a $4M round closed in June 2024 and a ~$2.93M round with Investissement Quebec, the New Brunswick Innovation Foundation, and Prevail Partners, and operates with a small team of 1-10 employees.

Name

Triple Hair

Legal name

Triple Hair Inc.

Website

https://triplehair.ca

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Triple Hair is a clinical-stage Canadian biotechnology company developing TH07, a patented triple-combination topical therapy (minoxidil, finasteride, latanoprost) for androgenic alopecia, currently in Phase III trials, with licensing deals in Brazil and India.

Ownership category

akta.pro rank

Product category

Hair Loss Treatments / Dermatological Pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411), Soap and Cleaning Compound Manufacturing (32561)

SIC

Perfumes, Cosmetics & Other Toilet Preparations (2844), Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics (2840)

akta.pro primary industry

Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth) (CRABABAE)

akta.pro secondary industry

Hair & Scalp Disorders (Trichology) (HLAKACAI)

Keywords

• Hair loss treatments
• Androgenic alopecia therapy
• Topical hair growth
• Clinical-stage biotechnology
• Hair regrowth solutions

Headquarters

HQ city

Dieppe

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Prescription Drug Sales (Therapy-07/TH07): Revenue from sales of patented prescription triple-combination topical therapy TH07 for male androgenic alopecia. Licensed to Aché in Brazil and Akums in India, with upfront payments, milestone payments, and royalty streams on future sales. The product is in Phase III clinical trials and not yet commercially launched.
2. Over-the-Counter Product Sales (RIZN & Plenty Natural): Sales of patented drug-free hair growth products under RIZN brand (for men) and Plenty Natural brand (for women). Products include topical spray, combo repousse, and vitamin complex. Sold directly through e-commerce (rizn.ca, plentynatural.ca) and distributed via white-label partnerships.
3. Licensing and Milestone Payments: Upfront payments and milestone payments from licensing agreements (Aché for Brazil, Akums for India). Additional revenues through 50:50 profit split on distribution sales and sublicense agreements with upfront milestone payments and royalties.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Triple Hair develops and commercializes patented topical therapies for androgenic alopecia (pattern hair loss). Its flagship prescription product TH07 combines minoxidil, finasteride, and latanoprost in a single topical spray and is currently in Phase III clinical trials in Canada and India. The company also sells drug-free over-the-counter products under the RIZN (men) and Plenty Natural (women) brands via owned e-commerce stores, and distributes prescription treatments through its Hair Loss Rx Consult telemedicine platform.

Product overview

Triple Hair is a clinical-stage Canadian biotechnology company developing a portfolio of hair growth treatments. The core prescription product is TH07 (Therapy-07), a patented topical spray combining minoxidil, finasteride, and latanoprost currently in Phase III clinical trials. The company also offers TH16 (Therapy-16), a drug-free natural formulation sold under the RIZN brand for men and Plenty Natural brand for women. A telemedicine platform called Hair Loss Rx Consult provides online access to prescription treatments. The company operates internationally through licensing agreements in Brazil (with Aché) and India (with Akums).

Differentiator

Problem solved

Functional benefit

Brands

• RIZN: Over-the-counter drug-free hair growth spray for men with early-stage hair loss
• Plenty Natural
• TH07
• TH16

Products and services

• TH07 (Therapy-07) Prescription topical spray combining minoxidil (5%), finasteride (0.1%), and latanoprost (0.03%) for treatment of male androgenic alopecia. Triple-combination therapy targeting multiple biological pathways involved in hair loss. Currently in Phase III clinical development.
• TH16 (Therapy-16)

Quantifiable outcome

• 82% of participants experienced positive outcomes (moderate to dense hair regrowth) in Phase II studies
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Aché Laboratorios Farmacêuticos S.A.coreOEM/ Whitelabel/ Licensing Partner · 23 June 2025Licensing agreement granting Aché exclusive rights to sell Triple Hair's Therapy-07 prescription drug in Brazil. Agreement comprises upfront payments, milestone payments, and royalties on potential future sales. Aché is one of Brazil's leading pharmaceutical companies with a strong presence in dermatological products, a top-selling minoxidil-based product, a robust sales force, and an extensive physician network.
• Akums Drugs & Pharmaceuticals Ltd.coreOEM/ Whitelabel/ Licensing Partner · 23 October 2024Strategic licensing partnership with India's largest CDMO for exclusive licensing of Therapy-07 in India. Akums funds regulatory and drug development costs, conducts ICH GCP Phase III clinical trial (380+ patients), and Triple Hair receives a 50:50 profit split on distribution sales and sublicense agreements with upfront milestone payments and royalties. Akums was later Triple Hair's clinical partner for the 500-patient India Phase III trial launched in 2026.
• OpportunitésNB (ONB)minorOthers · 27 July 2023New Brunswick government economic development organization that supported Triple Hair in obtaining patents, international expansion, and connections with investors. Part of the regional startup ecosystem (along with APECA and FINB) that backed the company, with 80% of investors based in New Brunswick.
• Pharmacy SolutionsminorChannel Partner/ Reseller/ Distributor · 21 June 2022Strategic agreement with a leading US compounding company to prepare and distribute Triple Hair's hair regrowth products (Therapy-07, RIZN, and Plenty Natural) in the United States. Pharmacy Solutions is a leader in compounding and distribution of pharmaceutical products.
• Endoceutics Pharma MSH Inc.coreStrategic or Co-development Partner · 16 April 2020Contract Manufacturing Organization (CMO) retained to support TH07 through clinical trials and eventual commercialization. Endoceutics is a world-renowned CMO with state-of-the-art facilities in Mont-St-Hilaire, Quebec, specializing in pharmaceutical formulation and manufacturing. Successfully completed a Phase 3 clinical trial with the FDA for Intrarosa product and is licensed to distribute steroids/androgens (relevant for finasteride component).

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Lexington International (HairMax): Markets FDA-cleared laser devices and topical hair-growth regimens for androgenic alopecia. Comparable as a consumer-facing brand addressing the same hair-loss category with non-systemic, technology-led solutions.
• Viviscal: Marketer of natural supplement and topical products for hair thinning in men and women. Comparable as an OTC hair-growth brand operating in the same consumer-driven hair-loss treatment category.
• Hims & Hers Health: DTC telehealth platform offering prescription and OTC hair-loss treatments including finasteride and minoxidil. Comparable business model overlap through Hair Loss Rx Consult telemedicine and direct e-commerce distribution of hair-loss products.

Emerging players

• Nutrafol: Sells clinically-tested natural hair-growth supplements and topical products for men and women. Comparable as a branded OTC hair-growth company pursuing the same consumer segments targeted by Triple Hair's RIZN and Plenty Natural brands.
• Prose: Direct-to-consumer personalized hair care brand including custom scalp and hair-thinning treatments. Comparable as a digital-first brand competing for the same hair-loss consumer wallet share, particularly among women.
• Cassiopea (Winlevi / clascoterone): Specialty dermatology company that brought topical clascoterone to market as a novel androgen-pathway inhibitor. Comparable as a clinical-stage dermatology innovator that advanced a topical, locally-acting androgen-targeting therapy to approval.

Broad incumbents

• Johnson & Johnson (Rogaine brand): Owner of Rogaine, the dominant minoxidil-based topical hair-loss brand reportedly controlling the majority of the US topical hair-growth market. Directly comparable as a topical therapy for androgenic alopecia, though it is part of J&J's much larger consumer health portfolio.
• Organon (Propecia / finasteride franchise): Marketer of Propecia (oral finasteride) for male pattern hair loss. Comparable as an approved prescription therapy for androgenic alopecia, the same indication Triple Hair is pursuing with topical TH07.
• Pfizer (Consumer Health / OTC hair portfolio): Major pharmaceutical company with prior consumer health exposure to hair-loss treatments and ongoing dermatology/clinical development capability. Comparable as a large incumbent with the resources to compete in androgenic alopecia therapeutics.

Others

• Aché Laboratórios Farmacêuticos: Brazilian pharmaceutical partner and licensee of Triple Hair's TH07. Listed here as a strategic partner/comparable for international dermatology distribution rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/TripleHairInc
• Facebookfacebook.com/triplehairinc
• LinkedInlinkedin.com/company/triple-hair-inc
• Instagraminstagram.com/triplehairinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Triple Hair